STING Agonism and B Cells in Liver Cancer: How Immune Activation Can Drive Both Tumor Control and Metastasis—and Why Targeting Regulatory B Cells Can Unlock Durable Anti-Tumor Immunity
Immunotherapy can potently activate anti-cancer immunity, yet liver cancer often resists it. Our new research reveals one reason why: STING agonism or PD1/VEGFR2 blockade increases regulatory B cells that suppress T cells. Targeting these B cells can restore the immune balance and block metastasis.